[Questionnaire-based survey on chemotherapy-induced anemia]

Area of Science:

• Oncology
• Hematology
• Clinical Medicine

Context:

• Chemotherapy-induced anemia (CIA) is a common complication in cancer patients.
• Blood transfusions are a primary treatment for severe anemia, but their use is restricted.
• A survey in Japan assessed transfusion practices for CIA across major cancer types.

Purpose:

• To evaluate the prevalence and patterns of red blood cell transfusion in cancer patients with chemotherapy-induced anemia.
• To analyze hemoglobin levels in patients receiving or not receiving transfusions.
• To identify limitations in current transfusion practices for CIA.

Summary:

• A 2010 survey of Japanese oncology and transfusion medicine societies revealed significant red blood cell utilization for CIA, with 7.5% of patients receiving transfusions.
• An estimated 146,000 units of red blood cells are transfused annually to CIA patients, representing 2.2% of the total supply.
• Despite 40% of chemotherapy patients having hemoglobin below 10 g/dL, transfusions were rarely given if hemoglobin was 8.0 g/dL or higher, and often withheld even at lower levels.

Impact:

• The study highlights restrictive red blood cell transfusion practices for CIA patients in Japan.
• Findings suggest a need for alternative treatments, such as erythropoiesis-stimulating agents, to manage CIA.
• Improving anemia management can enhance the quality of life for cancer patients undergoing chemotherapy.